The__O Virus.__B-MISC
Cytomegalovirus__O (CMV)__O is__O the__O major__O viral__O cause__O of__O congenital__O malformation.__O
Associated__O care__O costs__O $4.027__O billion/year__O in__O the__O US__B-LOC alone.__O
Infection__O is__O associated__O with__O life-threatening__O disease__O in__O the__O immunocompromised__O (most__O significantly__O transplant__O recipients__O and__O HIV-AIDS__B-ORG patients),__O and__O more__O than__O 95%__O of__O glioblastoma__O multiforme__O -__O the__O most__O common__O and__O aggressive__O form__O of__O brain__O tumour.__O
Moreover,__B-PER CMV__I-PER is__O an__O important__O cause__O of__O infectious__O mononucleosis,__O hepatitis,__O colitis,__O retinitis,__O arteriosclerosis__O and__O sensorineural__O hearing__O loss.__O
CMV__O also__O induces__O changes__O to__O the__O immune__O repertoire__O that__O contribute__O to__O autoimmune__O disease__O (arthritis)__O and__O immunosenescence.__O
The__O Problem:__O Lack__O of__O consistent__O measurement__O of__O CMV__O load.__O
Since__O CMV__O disease__O takes__O many__O forms,__O it__O lacks__O specific__O symptoms__O and__O diagnosis__O is__O absolutely__O dependent__O on__O laboratory__O testing.__O
With__O more__O than__O 50%__O of__O the__O adult__O population__O carrying__O a__O persistent__O infection,__O the__O presence__O of__O antibodies__O does__O not__O define__O disease.__O
PCR__O is__O therefore__O the__O key__O diagnostic__O test__O for__O defining__O CMV__B-ORG disease,__O and__O accurate__O quantification__O of__O virus__O load__O can__O be__O used__O to__O direct__O antiviral__O therapy__O and__O patient__O management__O (e.g.__O
removal/alleviation__O of__O immunosuppression__O in__O transplant__O recipients).__O
The__O CMV__O antivirals,__O such__O as__O Ganciclovir__O and__O Foscarnet,__B-ORG are__O associated__O with__O significant__O toxicity__O and__O resistance__O can__O arise__O rapidly.__O
Clinicians__O therefore__O need__O to__O use__O them__O with__O guidance__O from__O precise__O quantification__O of__O CMV__B-ORG load.__O
Before__O the__O Cardiff__B-LOC impact,__O CMV__B-ORG Q-PCR__I-ORG assays__O employed__O a__O diverse__O range__O of__O standards,__O including__O cloned__O fragments__O and__O assorted__O laboratory__O strains__O with__O varying__O experimental__O definitions__O of__O titre.__O
This__O lack__O of__O universal__O PCR__O test__O calibration__O prevented__O consensus__O or__O cooperative__O management__O of__O life-threatening__O infections__O across__O clinical__O centres.__O
So,__O in__O 2004,__O the__O International__B-ORG Herpesvirus__I-ORG Management__I-ORG Forum__I-ORG identified__O the__O urgent__O need__O for:__O "an__O international__O quantitation__O standard...to__O compare__O studies__O using__O different__O PCR-based__B-MISC systems__O and__O to__O facilitate__O patient__O management__O at__O multiple__O care__O centres"__O 5.1.__O
The__O Path__B-ORG to__I-ORG Impact__I-ORG -__O Providing__O a__O Genome__B-ORG Standard__I-ORG for__O the__O Pathogenic__B-ORG Herpesvirus__I-ORG Human__I-ORG Cytomegalovirus.__I-ORG
The__O importance__O of__O defining__O the__O genome__O of__O a__O CMV__B-ORG clinical__O isolate__O is__O evidenced__O by__O the__O adoption__O of__O this__O virus__O as__O the__O global__O PCR__B-ORG standard__O as__O well__O as__O more__O than__O 250__O citations__O of__O the__O original__O 2004__O sequence__O paper__O (although__O commonly__O only__O the__O accession__O number__O is__O referenced).__O
Since__O 2004,__O the__O annotated__O strain__O Merlin__B-ORG genome__O has__O been__O available__O through__O the__O World__B-ORG Health__I-ORG Organisation__I-ORG (WHO)__I-ORG reference__O library__O NIBSC.__B-ORG
Additionally,__O the__O viruses__O were__O deposited__O in__O virus__O banks__O run__O by__O the__O American__B-MISC Type__O Culture__B-PER Collection__I-PER and__O the__O European__B-ORG Collection__I-ORG of__I-ORG Cell__I-ORG Cultures,__I-ORG and__O thereby__O freely__O available__O to__O users__O worldwide.__O
This__O enabled__O resource__O distribution__O beyond__O academia,__O informing__O commercial__O development__O of__O vaccines__O and__O medicinal__O chemistry.__O
Impact:__O WHO__O adopts__O Strain__B-PER Merlin__I-PER as__O PCR__O Standard.__O
Following__O the__O warning__O by__O the__O International__B-ORG Herpesvirus__I-ORG Management__I-ORG forum,__O the__O WHO__B-ORG recognised__O the__O lack__O of__O CMV__B-ORG Standard__I-ORG as__O globally__O significant.__O
In__O 2008,__O the__O development__O of__O the__O first__O WHO__B-ORG International__I-ORG Standard__I-ORG for__I-ORG CMV__I-ORG was__O discussed__O at__O the__O Standardisation__B-ORG of__I-ORG Genomic__I-ORG Amplification__I-ORG Techniques__I-ORG Clinical__I-ORG Diagnostics__I-ORG meeting.__O
Participants__O agreed__O then__O that__O the__O optimal__O standard__O would__O "comprise__O a__O whole__O virus__O preparation__O of__O the__O prototype__O clinical__O HCMV__B-ORG strain__O Merlin".5.2a.__O
Subsequently,__O the__O WHO__B-ORG Expert__I-ORG Committee__I-ORG on__O Biological__O Standardization__O supported__O this__O recommendation:__O "the__O strain__O [Merlin]__B-ORG was__O chosen__O as__O it__O is__O well-characterised__O and__O more__O likely__O to__O represent__O a__O clinical__O virus__O than__O other__O laboratory-adapted__O strains"__O 5.2b.__O
In__O 2010,__O Wilkinson__B-ORG and__O Stanton__B-PER (Cardiff)__I-PER were__O formally__O acknowledged__O to__O have__O provided__O the__O WHO__B-ORG reference__O laboratory__O (NIBSC)__B-ORG with__O HCMV__B-ORG strains__O AD169__B-ORG and__O Merlin,__B-LOC the__O Merlin-BAC__B-ORG clone__O and__O technical__O and__O logistical__O advice__O on__O working__O with__O these__O reagents__O 5.2c,__O 5.3.__O
Merlin__O and__O other__O test__O candidate__O strains__O were__O evaluated__O in__O 32__O diagnostic,__O commercial__O and__O research__O laboratories__O in__O 14__O countries__O evaluated__O test__O candidates.__O
The__O recommendation__O stated:__O "...the__O results__O of__O the__O [collaborative]__B-MISC study__O indicate__O the__O suitability__O of__O the__O candidate__O HCMV__B-ORG Merlin__I-ORG standard__O as__O the__O proposed__O 1st__O WHO__B-ORG International__I-ORG Standard__I-ORG for__I-ORG HCMV.__I-ORG
It__O is__O therefore__O proposed__O that__O the__O candidate__O standard__O (NIBSC__B-ORG code__O 09/162)__O be__O established__O as__O the__O 1st__O WHO__B-ORG International__I-ORG Standard__I-ORG for__O HCMV...."5.2d__O Impact:__O Adoption__B-ORG of__I-ORG Merlin__I-ORG as__O calibration__O standard__O by__O the__O pharmaceutical__O industry.__O
Following__O adoption__O by__O the__O WHO,__B-ORG the__I-ORG CMV__I-ORG Merlin__I-ORG strain__O was__O then__O distributed__O by__O NIBSC__B-MISC as__O an__O international__O standard.__O
Between__O January__O 2011__O and__O April__O 2013,__O NIBSC__B-ORG shipped__O 960__O vials__O of__O the__O standard__O to__O 270__O diagnosis__O centres__O in__O 43__O countries.__O
In__O the__O next__O two__O years__O following__O WHO__B-ORG adoption,__O Merlin__B-PER was__O evaluated__O and__O implemented__O as__O a__O calibration__O standard__O in__O commercial__O Q-PCR__B-MISC testing__O assays__O by__O Cobas__B-PER Roche,__I-PER Abbott,__I-PER ABI__O Taqman,__B-PER Altona__I-PER Diagnostics__O (Germany)__O Biomerieux__O Argene,__B-PER Chiron,__I-PER and__O J&amp;J__B-LOC Diagnostics/Amersham__I-LOC Amerlite__I-LOC (Qiagen).__I-LOC
Promotional__O material__O for__O these__O devices__O now__O states__O they__O have__O been__O standardized__O to__O the__O first__O WHO__B-LOC international__O standard5.4.__O
The__O Roche__B-PER assay__O has__O now__O been__O approved__O by__O the__O FDA__B-ORG as__O a__O result__O of__O its__O calibration5.6.__O
The__O Abbott__B-PER assay__O has__O been__O approved__O for__O evaluation__O of__O a__O trial__O of__O a__O first-ever__O CMV__B-ORG vaccine__O trial5.5.__O
The__O Merlin__B-PER strain__O is__O also__O regularly__O distributed__O from__O Cardiff__B-LOC to__O support__O commercial__O research.__O
Since__O 2010,__O 35__O Material__B-ORG Transfer__I-ORG Agreements__I-ORG have__O been__O signed.__O
Impact:__B-ORG Benefits__I-ORG of__I-ORG Merlin__I-ORG in__O clinical__O management__O of__O CMV.__B-LOC
In__O 2011,__O a__O single__O London__B-LOC hospital__O (Royal__B-ORG Free)__I-ORG carried__O out__O approximately__O 10,000__O assays__O at__O a__O cost__O &#163;0.5M__B-MISC (Dr__B-ORG R.__I-ORG Milne,__I-ORG personal__O communication).__O
In__O the__O UK__B-LOC alone__O in__O the__O same__O year,__O 58__O centres__O carried__O out__O 252,303__O CMV__B-ORG diagnostic__O PCR__B-ORG tests,__O all__O now__O calibrated__O to__O the__O WHO__B-ORG standard;__O a__O market__O increasing__O 22%__O annually5.7.__O
The__O global__O market__O is__O proportionately__O larger.__O
The__O Cardiff__B-LOC research__O has__O therefore__O enabled__O greater__O validation__O and__O consistency__O in__O millions__O of__O tests__O conducted__O since__O 2010,__O improving__O the__O clinical__O management__O of__O CMV__B-LOC disease.__O
The__O commercial__O PCR__B-ORG assays,__O now__O calibrated__O against__O Merlin,__B-ORG allow__O more__O accurate__O assessment__O of__O viral__O load__O and__O thereby__O more__O precise__O use__O of__O antiviral__O therapy,__O reducing__O the__O risk__O of__O toxicity__O and__O resistance.__O
These__O clinical__O benefits__O of__O Merlin__B-PER as__O a__O CMV__B-ORG standard__O have__O been__O recognised__O in__O a__O growing__O number__O of__O studies.__O
One__O international__O multicenter__O evaluation__O 5.8,__O assessing__O the__O performance__O of__O the__O Roche__B-PER assay__O against__O non-calibrated__O tests,__O stated:__O "The__O implementation__O of__O an__O international__O standard__O and__O the__O availability__O of__O commercial__O QNAT__B-ORG [quantitative__O nucleic__O acid__O testing]__O with__O broad__O interlaboratory__O agreement__O that__O are__O traceable__O and__O colinear__O to__O the__O first__O WHO__B-LOC CMV__I-LOC international__O standard__O represent__O a__O much__O needed__O advancement."__O
An__O editorial__O to__O the__O same__O paper__O quotes:__O "With__O the__O availability__O of__O this__O test__O and__O the__O WHO__B-MISC International__I-MISC Standard__I-MISC for__O recalibrating__O LDTs__O [laboratory__O developed__O tests],__O the__O tools__O are__O now__O on__O hand__O to__O conduct__O multicenter__O clinical__O studies__O to__O establish__O clinical__O cutoffs__O for__O determining__O the__O risk__O of__O disease,__O diagnosing__O disease,__O and__O monitoring__O response__O to__O antiviral__O therapy.__O
"5.9__O http://cid.oxfordjournals.org/content/56/3/374.full.pdf+html__O (page__O 375)__O Another__O concludes:__O "Patients__O with__O pretreatment__O CMV__O DNA__O of__O &lt;18__O 200__O (4.3__O log10)__O IU/mL__O are__O 1.5__O times__O more__O likely__O to__O have__O CMV__O disease__O resolution.__O
CMV__O suppression__O (&lt;137__O [2.1__O log10]__O IU/mL),__B-ORG as__O measured__O by__O a__O test__O calibrated__O to__O the__O WHO__B-ORG Standard,__I-ORG is__O predictive__O of__O clinical__O response__O to__O antiviral__O treatment"__O http://cid.oxfordjournals.org/content/56/11/1546.full.pdf+html__O (page__O 1546,__O `Conclusions'__B-MISC paragraph__O on__O first__O page).__O
